Raju Willener appointed as CFO of VERAXA Biotech
News provided byVERAXA Biotech AG · 2 min read
Zurich, Switzerland, Sept. 04, 2026 /CourierPR/ -- VERAXA Biotech AG, a leading developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as Chief Financial Officer (CFO), effective immediately. Willener will report to Christoph Antz, Ph.D., the company's CEO and Co-Founder.
“We are delighted to welcome Raju at an important stage in the Company’s evolution,” said Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA. “His extensive experience in global capital markets, corporate finance, M&A, and investment management adds significant financial and strategic depth to our leadership team.”
Raju Willener brings over three decades of experience in finance and strategic leadership, including roles as Chief Financial Officer, Chief Investment Officer, Country Head, and Head of Corporate Finance across the U.S., Europe, and Asia. Prior to joining VERAXA, Willener served as Director of Corporate Development at Exentis Group AG, where he led M&A initiatives, financial strategy, and key corporate functions. He also held senior executive and investment leadership positions at top-tier global financial institutions and investment firms, managing assets under management exceeding CHF 30 billion.
“VERAXA has built a highly differentiated technology platform and a compelling oncology pipeline at an important stage of its development,” said Willener. “I am excited to join the Company and work alongside Christoph and the leadership team to further strengthen VERAXA’s financial and capital markets strategy, support disciplined capital allocation, and pursue strategic opportunities that can accelerate the development of a differentiated pipeline and create sustainable long-term value for shareholders.”
VERAXA is focused on advancing its pipeline of conditionally active T cell engagers (BiTAC-TCEs), bispecific antibody-drug conjugates (bsADCs), and proprietary BiTAC formats into clinical development. The company has implemented FDA-aligned New Approach Methodologies across all preclinical programs, enabling faster clinical advancement while reducing reliance on animal testing. Founded on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), VERAXA combines innovation with responsible research practices.
“With Raju’s expertise, we are well-positioned to optimize our capital strategy, evaluate strategic opportunities, and support disciplined execution and long-term shareholder value creation,” said Antz.
The company expressed gratitude to Carl von Halem, the former CFO, for his outstanding support during his tenure.
For regular updates about VERAXA Biotech, visit www.veraxa.com or follow the company on LinkedIn, X (formerly known as Twitter), and Bluesky.
BiTAC® is a registered trademark of VERAXA Biotech GmbH.
Forward-looking statements contained in this press release should be evaluated with the many uncertainties that affect the company’s business, particularly those identified or referenced in the risk factors section of the company’s most recent Annual Report on Form 20-F and any subsequent reports on Form 6-K.